IN8bio, Inc. (NASDAQ:INAB) Short Interest Update

IN8bio, Inc. (NASDAQ:INAB) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totaling 296,110 shares, an increase of 85.9% from the March 15th total of 159,244 shares. Based on an average daily trading volume, of 105,659 shares, the days-to-cover ratio is currently 2.8 days. Currently, 3.5% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of research firms recently issued reports on INAB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research note on Thursday, January 22nd. Zacks Research raised IN8bio to a “hold” rating in a research note on Thursday, January 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of IN8bio in a research note on Friday, March 13th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $4.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in INAB. HRT Financial LP purchased a new position in shares of IN8bio during the 4th quarter worth $34,000. Captrust Financial Advisors purchased a new position in shares of IN8bio during the 4th quarter worth $43,000. Citadel Advisors LLC purchased a new position in shares of IN8bio during the 3rd quarter worth $54,000. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of IN8bio during the 4th quarter worth $56,000. Finally, Two Sigma Investments LP purchased a new position in shares of IN8bio during the 3rd quarter worth $107,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Stock Performance

INAB stock opened at $1.39 on Monday. IN8bio has a 1 year low of $1.17 and a 1 year high of $5.82. The stock’s 50 day moving average price is $1.70 and its 200 day moving average price is $1.90. The firm has a market cap of $13.69 million, a P/E ratio of -0.31 and a beta of 0.04.

IN8bio (NASDAQ:INAB) last posted its earnings results on Thursday, March 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08). On average, research analysts predict that IN8bio will post -0.56 earnings per share for the current year.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.